Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective (Q34344855)

1 August 2017

1 reference

title

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective (English)

1 reference

1 August 2017

1 reference

2

Janet Woodcock

1 reference

1 August 2017

Lawrence J Lesko

1

1 reference

1 August 2017

1 September 2004

1 reference

Nature Reviews Drug Discovery

1 August 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

1 August 2017

3

1 reference

1 August 2017

763-769

1 reference

1 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1499

1 August 2017

0 references

cites work

The price of innovation: new estimates of drug development costs

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

21 January 2018

1 reference

Pharmacogenomic-guided drug development: regulatory perspective

21 January 2018

1 reference

Pharmacogenomics in Drug Development and Regulatory Decision-making: the Genomic Data Submission (GDS) Proposal.

31 March 2020

1 reference

Pharmacogenomic data: FDA voluntary and required submission guidance

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD1499

1 reference

1 August 2017

1 reference

PubMed ID

15340386